Liao Wenxin, Li Wei, Li Yang, Liu Tingting, Wang Ying, Feng Dan, Shen Fujin
Department of Obstetrics and Gynecology, Renmin Hospital of Wuhan University, Wuhan, 430060, Hubei, China.
J Cancer Res Clin Oncol. 2023 Jan;149(1):173-189. doi: 10.1007/s00432-022-04465-5. Epub 2022 Nov 9.
CD177, an indicator of prognosis in diverse cancers, is involved in the physiological processes of various tumor cells, and acts as an immune molecule with novel functions in cancer pathogenesis. However, the diagnostic, prognostic, and immunological role of CD177 in cervical cancer remains unclear.
Utilizing publicly available databases and integrating several bioinformatics analysis methods, we evaluated the expression level of CD177 in cervical cancer by GENT2, HPA, and GEO databases. And the experiments of western blot and immunohistochemical staining were used to test the hypothesis. The Kaplan-Meier Plotter database, Xena Shiny, and the constructed nomogram were clearly demonstrated its prognostic value for patients. Gene set enrichment analysis explored the relationship between CD177 and cervical cancer immune responses and immune cells infiltration level. In addition, we investigated the association between CD177 expression and stromal score, immune score, immune checkpoint, and drug sensitivity by TCGA RNA-seq data.
CD177 was apparently expressed at low levels in cervical cancer and predicted a poor survival rate for patients. CD177 significantly activated immune-related signaling pathways and had a positive relationship with immune cell infiltration level. The high CD177 expression group possessed the high stromal score and immune score. CD177 had potential interactions with CTLA4, CD27, BLTA, CD200R1, CD80, NRP1, TNFRSF25, TIGIT, ICOS, and TNFSF9 checkpoint markers. And CD177 expression was positively relevant with drug sensitivity for Lapatinib, Belinostat, ATRA, Gefitinib, Navitoclax, and Tamoxifen.
These findings may shed light on the vital role of CD177 in cervical cancer diagnosis, prognosis, and immunological functions, and it may be a promising predictor and potential factor for cervical cancer patients.
CD177是多种癌症预后的指标，参与各种肿瘤细胞的生理过程，并在癌症发病机制中作为具有新功能的免疫分子发挥作用。然而，CD177在宫颈癌中的诊断、预后和免疫作用仍不清楚。
利用公开可用的数据库并整合多种生物信息学分析方法，我们通过GENT2、HPA和GEO数据库评估了宫颈癌中CD177的表达水平。并使用蛋白质免疫印迹和免疫组织化学染色实验来验证这一假设。Kaplan-Meier Plotter数据库、Xena Shiny和构建的列线图清楚地证明了其对患者的预后价值。基因集富集分析探讨了CD177与宫颈癌免疫反应及免疫细胞浸润水平之间的关系。此外，我们通过TCGA RNA测序数据研究了CD177表达与基质评分、免疫评分、免疫检查点和药物敏感性之间的关联。
CD177在宫颈癌中明显低表达，提示患者生存率较差。CD177显著激活免疫相关信号通路，与免疫细胞浸润水平呈正相关。CD177高表达组具有较高的基质评分和免疫评分。CD177与CTLA4、CD27、BLTA、CD200R1、CD80、NRP1、TNFRSF25、TIGIT、ICOS和TNFSF9检查点标志物存在潜在相互作用。并且CD177表达与拉帕替尼、贝利司他、全反式维甲酸、吉非替尼、纳维托克司和他莫昔芬的药物敏感性呈正相关。
这些发现可能揭示CD177在宫颈癌诊断、预后和免疫功能中的重要作用，它可能是宫颈癌患者一个有前景的预测指标和潜在因素。
